fingolimod hydrochloride has been researched along with glutamic acid in 8 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (glutamic acid) | Trials (glutamic acid) | Recent Studies (post-2010) (glutamic acid) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 41,757 | 452 | 12,876 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | glutamic acid (IC50) |
|---|---|---|---|
| Chain A, GLUTAMATE RECEPTOR SUBUNIT 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Chain A, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Chain B, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Metabotropic glutamate receptor 8 | Homo sapiens (human) | 0.0057 | |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | 0.07 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor 1 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor 2 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor 3 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 0.38 | |
| Excitatory amino acid transporter 1 | Homo sapiens (human) | 207 | |
| Glutamate receptor 4 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1533 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassilana, F; Cortes-Cros, M; Craveiro, LM; Dev, KK; Guerini, D; Mullershausen, F; Osinde, M; Schwab, ME; Seuwen, K; Shin, Y; Sivasankaran, R; Thallmair, M; Wishart, WL | 1 |
| Bernardi, G; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Motta, C; Musella, A; Rossi, S; Studer, V | 1 |
| Davletov, B; Kreft, M; Parpura, V; Potokar, M; Stenovec, M; Trkov, S; Zorec, R | 1 |
| Falato, E; Filippi, MM; Ghazaryan, A; Landi, D; Mulas, D; Pasqualetti, P; Pellegrino, G; Rossini, PM; Vollaro, S | 1 |
| Bonanno, G; Bonfiglio, T; Di Cesare Mannelli, L; Di Prisco, S; Ghelardini, C; Grilli, M; Marchi, M; Merega, E; Milanese, M; Olivero, G; Padolecchia, C; Pittaluga, A | 1 |
| Bal, M; Darios, FD; Davletov, B; Flašker, A; García-Martinez, V; Gutiérrez, LM; Jorgacevski, J; Kavalali, ET; Leese, C; Nosyreva, E; Villanueva, J; Zorec, R | 1 |
| Dąbrowska-Bouta, B; Strosznajder, R; Struzynska, L; Sulkowski, G; Wencel, PL | 1 |
| Olivero, G; Pittaluga, A; Roggeri, A; Usai, C; Vanmierlo, T | 1 |
8 other study(ies) available for fingolimod hydrochloride and glutamic acid
| Article | Year |
|---|---|
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Astrocytes; beta-Alanine; Calcium Signaling; Cell Movement; Cell Proliferation; Cells, Cultured; Cerebral Cortex; Cyclic AMP; Dose-Response Relationship, Drug; Embryo, Mammalian; Fingolimod Hydrochloride; Glial Fibrillary Acidic Protein; Glutamic Acid; Hippocampus; Immunosuppressive Agents; Inositol Phosphates; Organ Culture Techniques; Oxadiazoles; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2007 |
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
Topics: Animals; Dendritic Spines; Encephalomyelitis, Autoimmune, Experimental; Excitatory Postsynaptic Potentials; Female; Fingolimod Hydrochloride; Glutamic Acid; Glycoproteins; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Sphingosine; Synapses; Synaptic Transmission | 2012 |
Fingolimod--a sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Topics: Animals; Astrocytes; Calcium; Dose-Response Relationship, Drug; Exocytosis; Fingolimod Hydrochloride; Glutamic Acid; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Transport Vesicles | 2012 |
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Animals; Evoked Potentials, Motor; Female; Fingolimod Hydrochloride; Glutamic Acid; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Prospective Studies; Sphingosine; Transcranial Magnetic Stimulation | 2015 |
Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
Topics: Administration, Oral; Animals; Cerebral Cortex; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Exocytosis; Female; Fingolimod Hydrochloride; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Neuroglia; Organ Specificity; Spinal Cord; Synapses | 2017 |
Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion.
Topics: Animals; Cytosol; Excitatory Postsynaptic Potentials; Exocytosis; Fingolimod Hydrochloride; Glutamic Acid; Hippocampus; Male; Multiple Sclerosis; Neurons; Neurosecretory Systems; R-SNARE Proteins; Rats, Wistar; SNARE Proteins; Sphingosine; Synaptic Vesicles; Synaptosomes | 2017 |
Alterations in the transcriptional profile of genes related to glutamatergic signalling in animal models of Alzheimer's disease. The effect of fingolimod.
Topics: Alzheimer Disease; Animals; Fingolimod Hydrochloride; Glutamic Acid; Mice; Models, Animal; Signal Transduction | 2022 |
Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glutamic Acid; Mice; Sphingosine-1-Phosphate Receptors | 2023 |